Rapid Micro Biosystems (RPID) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

RPID Stock Forecast


Rapid Micro Biosystems stock forecast is as follows: an average price target of $8.00 (represents a 858.08% upside from RPID’s last price of $0.83) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

RPID Price Target


The average price target for Rapid Micro Biosystems (RPID) is $8.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 858.08% upside from RPID's last price of $0.83.

RPID Analyst Ratings


Hold

According to 1 Wall Street analysts, Rapid Micro Biosystems's rating consensus is 'Hold'. The analyst rating breakdown for RPID stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rapid Micro Biosystems Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 11, 2022-Morgan Stanley$8.00$4.1194.65%858.08%
Row per page
Go to

The latest Rapid Micro Biosystems stock forecast, released on May 11, 2022 by Morgan Stanley company, set a price target of $8.00, which represents a 94.65% increase from the stock price at the time of the forecast ($4.11), and a 858.08% increase from RPID last price ($0.83).

Rapid Micro Biosystems Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.83$0.83$0.83
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Rapid Micro Biosystems stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rapid Micro Biosystems's last price of $0.83. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 11, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Row per page
Go to

Rapid Micro Biosystems's last stock rating was published by Morgan Stanley on May 11, 2022. The company gave RPID a "Equal-Weight" rating, the same as its previous rate.

Rapid Micro Biosystems Financial Forecast


Rapid Micro Biosystems Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue--------$6.34M$6.14M$5.00M$5.04M$4.37M$4.74M$3.86M$4.16M$5.21M$6.90M$6.13M
Avg Forecast$7.82M$7.61M$7.40M$7.19M$8.40M$6.55M$6.00M$5.50M$6.15M$5.55M$4.15M$4.13M$4.50M$3.97M$4.35M$5.16M$5.87M$6.57M$5.93M
High Forecast$8.12M$7.90M$7.68M$7.47M$8.72M$6.58M$6.23M$5.71M$6.23M$5.76M$4.31M$4.29M$4.67M$4.12M$4.44M$5.27M$5.99M$6.71M$6.06M
Low Forecast$7.52M$7.31M$7.11M$6.92M$8.08M$6.52M$5.77M$5.29M$6.07M$5.34M$3.99M$3.98M$4.33M$3.82M$4.26M$5.05M$5.74M$6.42M$5.80M
# Analysts----12112111----111
Surprise %--------1.03%1.11%1.21%1.22%0.97%1.19%0.89%0.81%0.89%1.05%1.03%

Rapid Micro Biosystems's average Quarter revenue forecast for Mar 24 based on 1 analysts is $5.50M, with a low forecast of $5.29M, and a high forecast of $5.71M. RPID's average Quarter revenue forecast represents a -13.21% decrease compared to the company's last Quarter revenue of $6.34M (Dec 23).

Rapid Micro Biosystems EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts----12112111----111
EBITDA--------$-12.48M$-14.45M$-15.05M$-14.87M$-17.26M$-16.15M$-13.69M$-14.34M$-14.14M$-25.36M$-10.54M
Avg Forecast$-7.82M$-7.61M$-7.40M$-7.19M$-8.40M$-6.55M$-6.00M$-5.50M$-6.15M$-5.55M$-4.15M$-4.13M$-4.50M$-27.16M$-4.35M$-13.47M$-5.87M$-6.57M$-443.86M
High Forecast$-7.52M$-7.31M$-7.11M$-6.92M$-8.08M$-6.52M$-5.77M$-5.29M$-6.07M$-5.34M$-3.99M$-3.98M$-4.33M$-21.73M$-4.26M$-10.77M$-5.74M$-6.42M$-355.09M
Low Forecast$-8.12M$-7.90M$-7.68M$-7.47M$-8.72M$-6.58M$-6.23M$-5.71M$-6.23M$-5.76M$-4.31M$-4.29M$-4.67M$-32.59M$-4.44M$-16.16M$-5.99M$-6.71M$-532.64M
Surprise %--------2.03%2.60%3.63%3.60%3.84%0.59%3.15%1.06%2.41%3.86%0.02%

undefined analysts predict RPID's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Rapid Micro Biosystems's previous annual EBITDA (undefined) of $NaN.

Rapid Micro Biosystems Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts----12112111----111
Net Income--------$-11.17M$-13.39M$-14.02M$-13.89M$-16.45M$-16.34M$-13.09M$-14.93M$-14.61M$-24.99M$-11.83M
Avg Forecast$-7.85M$-8.29M$-8.29M$-9.60M$-10.03M$-10.56M$-12.07M$-12.65M$-12.55M$-13.38M$-14.83M$-15.92M$-15.70M$-26.76M$-13.85M$-14.03M$-12.21M$-16.90M$-498.37M
High Forecast$-7.46M$-7.88M$-7.88M$-9.12M$-9.53M$-10.50M$-11.47M$-12.02M$-12.44M$-12.71M$-14.09M$-15.13M$-14.92M$-21.41M$-13.46M$-11.22M$-11.87M$-16.42M$-398.70M
Low Forecast$-8.24M$-8.70M$-8.70M$-10.07M$-10.53M$-10.62M$-12.67M$-13.28M$-12.66M$-14.04M$-15.57M$-16.71M$-16.48M$-32.11M$-14.24M$-16.83M$-12.56M$-17.38M$-598.05M
Surprise %--------0.89%1.00%0.95%0.87%1.05%0.61%0.95%1.06%1.20%1.48%0.02%

Rapid Micro Biosystems's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RPID's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Rapid Micro Biosystems SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts----12112111----111
SG&A--------$8.70M$9.70M$9.93M$9.93M$11.26M$11.12M$9.89M$9.55M$9.12M$8.37M$6.75M
Avg Forecast$11.25M$10.94M$10.64M$10.35M$12.09M$9.43M$8.63M$7.91M$8.85M$7.99M$5.97M$5.95M$6.48M$5.71M$6.26M$7.43M$8.44M$9.45M$8.54M
High Forecast$11.68M$11.36M$11.05M$10.75M$12.55M$9.47M$8.96M$8.22M$8.97M$8.29M$6.20M$6.18M$6.72M$5.93M$6.40M$7.59M$8.63M$9.66M$8.72M
Low Forecast$10.82M$10.53M$10.24M$9.96M$11.63M$9.38M$8.30M$7.61M$8.73M$7.68M$5.74M$5.72M$6.23M$5.49M$6.12M$7.27M$8.26M$9.24M$8.35M
Surprise %--------0.98%1.21%1.66%1.67%1.74%1.95%1.58%1.29%1.08%0.89%0.79%

Rapid Micro Biosystems's average Quarter SG&A projection for Mar 24 is $7.91M, based on 1 Wall Street analysts, with a range of $7.61M to $8.22M. The forecast indicates a -9.01% fall compared to RPID last annual SG&A of $8.70M (Dec 23).

Rapid Micro Biosystems EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts----12112111----111
EPS--------$-0.00$-0.31$-0.33$-0.32$-0.39$-0.38$-0.31$-0.35$-0.35$-0.71$-0.31
Avg Forecast$-0.18$-0.19$-0.19$-0.22$-0.23$-0.24$-0.28$-0.29$-0.29$-0.31$-0.34$-0.36$-0.36$-0.37$-0.32$-0.34$-0.28$-0.39$-1.09
High Forecast$-0.17$-0.18$-0.18$-0.21$-0.22$-0.24$-0.26$-0.28$-0.29$-0.29$-0.32$-0.35$-0.34$-0.35$-0.31$-0.33$-0.27$-0.38$-1.06
Low Forecast$-0.19$-0.20$-0.20$-0.23$-0.24$-0.24$-0.29$-0.30$-0.29$-0.32$-0.36$-0.38$-0.38$-0.38$-0.33$-0.35$-0.29$-0.40$-1.12
Surprise %--------0.00%1.01%0.97%0.88%1.08%1.04%0.98%1.04%1.25%1.83%0.28%

According to undefined Wall Street analysts, Rapid Micro Biosystems's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RPID previous annual EPS of $NaN (undefined).

Rapid Micro Biosystems Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BJDXBluejay Diagnostics$0.15$10.006566.67%Buy
OWLTOwlet$4.03$196.004763.52%Buy
RPIDRapid Micro Biosystems$0.84$8.00852.38%Hold
AZYOElutia$1.49$10.25587.92%Buy
OFIXOrthofix Medical$16.76$31.0084.96%-
LUNGPulmonx$8.31$12.2547.41%Buy
LIVNLivaNova$48.53$71.2546.82%Buy
KIDSOrthoPediatrics$32.28$40.8026.39%Buy
RXSTRxSight$54.96$68.6024.82%Buy
SRDXSurmodics$39.36$39.500.36%Buy
BVSBioventus$11.17$7.50-32.86%Buy

RPID Forecast FAQ


No, according to 1 Wall Street analysts, Rapid Micro Biosystems (RPID) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of RPID's total ratings.

Rapid Micro Biosystems (RPID) average price target is $8 with a range of $8 to $8, implying a 858.08% from its last price of $0.835. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for RPID stock, the company can go up by 858.08% (from the last price of $0.835 to the average price target of $8), up by 858.08% based on the highest stock price target, and up by 858.08% based on the lowest stock price target.

RPID's average twelve months analyst stock price target of $8 supports the claim that Rapid Micro Biosystems can reach $1 in the near future.

Rapid Micro Biosystems's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.45M (high $27.24M, low $25.66M), average EBITDA is $-26.45M (high $-25.659M, low $-27.241M), average net income is $-45.311M (high $-43.525M, low $-47.097M), average SG&A $38.06M (high $39.2M, low $36.92M), and average EPS is $-1.039 (high $-0.998, low $-1.08). RPID's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $30.01M (high $31.16M, low $28.87M), average EBITDA is $-30.015M (high $-28.869M, low $-31.16M), average net income is $-34.021M (high $-32.332M, low $-35.709M), average SG&A $43.19M (high $44.84M, low $41.54M), and average EPS is $-0.78 (high $-0.741, low $-0.819).

Based on Rapid Micro Biosystems's last annual report (Dec 2023), the company's revenue was $22.52M, beating the average analysts forecast of $19.98M by 12.69%. Apple's EBITDA was $-56.563M, beating the average prediction of $-19.983M by 183.05%. The company's net income was $-52.467M, missing the average estimation of $-56.675M by -7.42%. Apple's SG&A was $38.26M, beating the average forecast of $28.76M by 33.04%. Lastly, the company's EPS was $-0.0012, missing the average prediction of $-1.299 by -99.91%. In terms of the last quarterly report (Dec 2023), Rapid Micro Biosystems's revenue was $6.34M, beating the average analysts' forecast of $6.15M by 3.04%. The company's EBITDA was $-12.483M, beating the average prediction of $-6.15M by 102.98%. Rapid Micro Biosystems's net income was $-11.172M, missing the average estimation of $-12.549M by -10.97%. The company's SG&A was $8.7M, missing the average forecast of $8.85M by -1.72%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.288 by -99.90%